Adenosine-5'-(N-ethylcarboxamide)
"Adenosine-5'-(N-ethylcarboxamide)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.
| Descriptor ID |
D019830
|
| MeSH Number(s) |
D03.633.100.759.590.138.025 D13.570.583.138.025 D13.570.800.096.250
|
| Concept/Terms |
Adenosine-5'-(N-ethylcarboxamide)- Adenosine-5'-(N-ethylcarboxamide)
- N6-Ethyl-carboxamido Adenosine
- Adenosine, N6-Ethyl-carboxamido
- N6 Ethyl carboxamido Adenosine
- NECA
- Adenosine-5'-N-ethyluronamide
- Adenosine 5' N ethyluronamide
- 5'-N-Ethylcarboxamidoadenosine
- 5' N Ethylcarboxamidoadenosine
- N-Ethylcarboxamidoadenosine
- N Ethylcarboxamidoadenosine
|
Below are MeSH descriptors whose meaning is more general than "Adenosine-5'-(N-ethylcarboxamide)".
Below are MeSH descriptors whose meaning is more specific than "Adenosine-5'-(N-ethylcarboxamide)".
This graph shows the total number of publications written about "Adenosine-5'-(N-ethylcarboxamide)" by people in this website by year, and whether "Adenosine-5'-(N-ethylcarboxamide)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenosine-5'-(N-ethylcarboxamide)" by people in Profiles.
-
Hua X, Chason KD, Fredholm BB, Deshpande DA, Penn RB, Tilley SL. Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. J Allergy Clin Immunol. 2008 Jul; 122(1):107-13, 113.e1-7.
-
Hua X, Erikson CJ, Chason KD, Rosebrock CN, Deshpande DA, Penn RB, Tilley SL. Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. Am J Physiol Lung Cell Mol Physiol. 2007 Jul; 293(1):L25-32.
-
Penn RB, Pascual RM, Kim YM, Mundell SJ, Krymskaya VP, Panettieri RA, Benovic JL. Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. J Biol Chem. 2001 Aug 31; 276(35):32648-56.
-
Mundell SJ, Olah ME, Panettieri RA, Benovic JL, Penn RB. Regulation of G protein-coupled receptor-adenylyl cyclase responsiveness in human airway smooth muscle by exogenous and autocrine adenosine. Am J Respir Cell Mol Biol. 2001 Feb; 24(2):155-63.
-
Mundell SJ, Matharu AL, Kelly E, Benovic JL. Arrestin isoforms dictate differential kinetics of A2B adenosine receptor trafficking. Biochemistry. 2000 Oct 24; 39(42):12828-36.
-
Mundell SJ, Benovic JL, Kelly E. A dominant negative mutant of the G protein-coupled receptor kinase 2 selectively attenuates adenosine A2 receptor desensitization. Mol Pharmacol. 1997 Jun; 51(6):991-8.
-
Parkinson SJ, Alekseev AE, Gomez LA, Wagner F, Terzic A, Waldman SA. Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine. J Biol Chem. 1997 Jan 10; 272(2):754-8.
-
Palmer TM, Benovic JL, Stiles GL. Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. J Biol Chem. 1995 Dec 08; 270(49):29607-13.
-
D'Ancona S, Ragazzi E, Fassina G, Mazzo M, Gusella M, Berti T. Effect of dipyridamole, 5'-(N-ethyl)-carboxamidoadenosine and 1,3-dipropyl-8-(2-amino-4-chlorophenyl)-xanthine on LOVO cell growth and morphology. Anticancer Res. 1994 Jan-Feb; 14(1A):93-7.
-
Cronstein BN, Kramer SB, Rosenstein ED, Korchak HM, Weissmann G, Hirschhorn R. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem J. 1988 Jun 15; 252(3):709-15.